Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically confirmed neuroendocrine tumor OR characteristic radiological findings
of neuroendocrine tumor with raised hormone levels in plasma or urine meeting any of
the following criteria:

- Primary disease in gut with liver metastases (with or without hormone secretion)

- Primary disease in lung with liver or abdominal metastases (with or without
hormone secretion)

- Primary disease in pancreas with or without metastases (with or without hormone
secretion)

PATIENT CHARACTERISTICS:

- Any Karnofsky performance status allowed

- Life expectancy ≥ 3 months

- Able to understand the questionnaire language

- Mentally fit to complete questionnaire

- No psychological, familial, sociological, or geographical condition that would limit
study compliance

- No other concurrent malignancies except basal cell carcinoma of the skin

PRIOR CONCURRENT THERAPY:

- More than 2 months since prior somatostatin analogue or interferon therapy
(somatostatin therapy stratum)

- Concurrent somatostatin analogue and/or interferon therapy allowed if dose
stable over the past month

- More than 6 months since prior radionuclide therapy or systemic chemotherapy
(radionuclide or systemic chemotherapy stratum)

- More than 6 months since prior ablative therapies (ablative therapy stratum)

- No concurrent participation in other quality of life studies